4244例COVID-19危重成人的临床特征与90天结局:一项前瞻性队列研究
COVID-ICU是一项在法国、比利时和瑞士138家医院开展的多中心前瞻性队列研究,纳入4643例ICU收治的实验室确诊COVID-19患者,其中4244例有90天生存状态。ICU入科时29%接受标准氧疗、19%经鼻高流量氧疗、6%无创通气;63%在24小时内插管,80%在ICU期间接受有创机械通气。90天死亡率为31%,研究期间从42%降至25%。入ICU当天接受有创或无创通气的患者中,90天死亡率随ARDS严重程度(轻、中、重)分别为30%、34%和50%。
要点
- ICU入科当天接受通气支持的患者,90天死亡率随ARDS严重程度递增:轻度30%、中度34%、重度50%。
- 总体90天死亡率为31%(1298/4244),研究期间从42%下降至25%。
- 早期独立预测90天死亡的因素包括:高龄、免疫抑制、重度肥胖、糖尿病、较高的肾脏和心血管SOFA评分成分、较低的PaO2/FiO2比值、以及从首发症状到ICU入院时间较短。
- 有创机械通气期间中位PEEP为12 cmH2O、中位平台压为24 cmH2O,机械功率为26.5 J/min;第1天插管患者中88%使用肌松剂、70%实施俯卧位。
- 插管患者中肺栓塞诊断率9%(207例)、呼吸机相关性肺炎诊断率58%(1209例)。
适用人群与场景
- 2020年2月25日至5月4日在法国、比利时和瑞士138家医院ICU收治的实验室确诊COVID-19成人患者,共4643例,其中4244例有ICU入科后90天生存状态数据。
- 中位年龄63岁(IQR 54-71),中位SAPS II评分37(IQR 28-50)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- ICU入科时呼吸支持方式:29%接受标准氧疗、19%接受经鼻高流量氧疗、6%接受无创通气。
- 63%(2635例)在入ICU后24小时内插管,80%(3376例)在ICU期间至少接受一次有创机械通气。
- 有创机械通气中位PEEP为12 cmH2O(IQR 10-14),中位平台压为24 cmH2O(IQR 21-27),机械功率为26.5 J/min(IQR 18.6-34.9)。
- 第1天插管患者中88%使用肌松剂,70%实施俯卧位。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:多中心前瞻性队列研究,纳入138家医院、4643例ICU收治的COVID-19患者,其中4244例有90天生存状态。
- 主要结局:90天死亡率为31%(1298/4244);研究期间死亡率从42%下降至25%。
- 入ICU当天接受有创或无创通气的患者中,90天死亡率随ARDS严重程度递增:轻度30%、中度34%、重度50%。
- 早期独立预测90天死亡的因素:高龄、免疫抑制、重度肥胖、糖尿病、较高的肾脏和心血管SOFA评分成分、较低的PaO2/FiO2比值、以及从首发症状到ICU入院时间较短。
- 插管患者中诊断肺栓塞207例(9%)、呼吸机相关性肺炎1209例(58%)。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究。
- 局限:原文未提及具体局限性说明;观察性设计无法确立因果关系。
对床旁实践的改变
- 该队列提示COVID-19危重患者90天死亡率随ARDS严重程度增加而升高(轻度30%、中度34%、重度50%),可作为ICU入科时与家属沟通预后的参考。
- 早期独立预测因素(高龄、免疫抑制、重度肥胖、糖尿病、较高的肾脏和心血管SOFA评分成分、较低的PaO2/FiO2比值、症状到ICU时间较短)可用于识别高危患者,但研究为观察性设计,不能据此推断干预效果。
- 原文未提及具体治疗推荐或方案变更,仅描述性报告了呼吸支持参数(中位PEEP 12 cmH2O、平台压24 cmH2O、机械功率26.5 J/min)及辅助措施使用率(肌松剂88%、俯卧位70%),不构成床旁推荐。
指南或共识出处
- COVID-ICU多中心前瞻性队列研究(法国、比利时、瑞士138家医院),发表于Intensive Care Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To describe acute respiratory distress syndrome (ARDS) severity, ventilation management, and the outcomes of ICU patients with laboratory-confirmed COVID-19 and to determine risk factors of 90-day mortality post-ICU admission.
METHODS: COVID-ICU is a multi-center, prospective cohort study conducted in 138 hospitals in France, Belgium, and Switzerland. Demographic, clinical, respiratory support, adjunctive interventions, ICU length-of-stay, and survival data were collected.
RESULTS: From February 25 to May 4, 2020, 4643 patients (median [IQR] age 63 [54-71] years and SAPS II 37 [28-50]) were admitted in ICU, with day-90 post-ICU admission status available for 4244. On ICU admission, standard oxygen therapy, high-flow oxygen, and non-invasive ventilation were applied to 29%, 19%, and 6% patients, respectively. 2635 (63%) patients were intubated during the first 24 h whereas overall 3376 (80%) received invasive mechanical ventilation (MV) at one point during their ICU stay. Median (IQR) positive end-expiratory and plateau pressures were 12 (10-14) cmH2O, and 24 (21-27) cmH2O, respectively. The mechanical power transmitted by the MV to the lung was 26.5 (18.6-34.9) J/min. Paralyzing agents and prone position were applied to 88% and 70% of patients intubated at Day-1, respectively. Pulmonary embolism and ventilator-associated pneumonia were diagnosed in 207 (9%) and 1209 (58%) of these patients. On day 90, 1298/4244 (31%) patients had died. Among patients who received invasive or non-invasive ventilation on the day of ICU admission, day-90 mortality increased with the severity of ARDS at ICU admission (30%, 34%, and 50% for mild, moderate, and severe ARDS, respectively) and decreased from 42 to 25% over the study period. Early independent predictors of 90-day mortality were older age, immunosuppression, severe obesity, diabetes, higher renal and cardiovascular SOFA score components, lower PaO2/FiO2 ratio and a shorter time between first symptoms and ICU admission.
CONCLUSION: Among more than 4000 critically ill patients with COVID-19 admitted to our ICUs, 90-day mortality was 31% and decreased from 42 to 25% over the study period. Mortality was higher in older, diabetic, obese and severe ARDS patients.
参考来源
- Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2020. PMID: 33211135. doi:10.1007/s00134-020-06294-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。